Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.

作者信息

Stagno F, Vigneri P, Del Fabro V, Stella S, Massimino M, Berretta S, Cupri A, Consoli C, Messina L, Tirrò E, Messina A, Di Raimondo F

出版信息

Leuk Res. 2009 Sep;33(9):e157-8. doi: 10.1016/j.leukres.2009.03.040. Epub 2009 Apr 29.

DOI:10.1016/j.leukres.2009.03.040

PMID:19406471

Abstract

摘要

相似文献

Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.

Leuk Res. 2009 Sep;33(9):e157-8. doi: 10.1016/j.leukres.2009.03.040. Epub 2009 Apr 29.

Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.

Clin Chem. 2004 Jul;50(7):1233-7. doi: 10.1373/clinchem.2004.034801.

BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.用于预测慢性髓性白血病患者在伊马替尼治疗失败后对第二代酪氨酸激酶抑制剂反应的BCR-ABL突变研究。

Hong Kong Med J. 2009 Oct;15(5):365-73.

Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.一名对STI571耐药性增加的慢性髓性白血病患者中BCR-ABL的ATP结合位点发生突变。

Br J Haematol. 2002 Oct;119(1):109-11. doi: 10.1046/j.1365-2141.2002.03708.x.

Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?在伴有 Bcr-Abl 激酶结构域突变的伊马替尼耐药慢性髓性白血病患者中选择最佳的二线酪氨酸激酶抑制剂：IC₅₀的可靠性如何？

Oncologist. 2011;16(6):868-76. doi: 10.1634/theoncologist.2010-0388. Epub 2011 May 31.

Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.附加染色体异常和 BCR-ABL 激酶结构域突变对费城染色体阳性慢性髓性白血病患者接受尼罗替尼治疗反应的影响。

Haematologica. 2010 Apr;95(4):582-8. doi: 10.3324/haematol.2009.014712. Epub 2009 Dec 16.

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.韩国慢性髓性白血病患者在接受 Abl 酪氨酸激酶抑制剂治疗期间 T315I BCR-ABL 激酶结构域突变的动态变化。

Hematol Oncol. 2010 Jun;28(2):82-8. doi: 10.1002/hon.918.

A novel I293MP mutation within BCR-ABL kinase domain in a Ph-positive acute lymphoblastic leukemia patient presenting resistant to imatinib but sensitive to nilotinib.一名Ph阳性急性淋巴细胞白血病患者的BCR-ABL激酶结构域内存在一种新的I293MP突变，该患者对伊马替尼耐药，但对尼罗替尼敏感。

Leuk Res. 2012 Aug;36(8):e159-62. doi: 10.1016/j.leukres.2012.04.019. Epub 2012 May 11.

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.BCR-ABL中伊马替尼耐药突变的机制及影响

Curr Opin Hematol. 2004 Jan;11(1):35-43. doi: 10.1097/00062752-200401000-00006.

E255K and G250E mutation appearing in a patient with e19a2 chronic myeloid leukemia resistant to imatinib.在一名对伊马替尼耐药的e19a2慢性髓性白血病患者中出现的E255K和G250E突变。

Clin Lab. 2015;61(1-2):183-6. doi: 10.7754/clin.lab.2014.140818.

引用本文的文献

Targeting BCL-2 as a Therapeutic Strategy for Primary -positive B-ALL Cells.针对 BCL-2 作为治疗原发性 B 细胞急性淋巴细胞白血病细胞的策略。

In Vivo. 2020 Mar-Apr;34(2):511-516. doi: 10.21873/invivo.11802.

Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.成功管理接受标准剂量伊马替尼治疗的慢性髓性白血病孕妇。

In Vivo. 2019 Sep-Oct;33(5):1593-1598. doi: 10.21873/invivo.11641.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验